Drugs Made In America Acquisition Corp. 8-K

What Happened Drugs Made In America Acquisition Corp. (the “Company”) filed an 8-K on April 8, 2026 reporting it entered into a letter of intent (LOI) with Power Analytics Global Corp., a Delaware corporation (the “Target”), to pursue a de‑SPAC business combination that would result in the Target becoming a public company. The LOI anticipates a Target valuation of approximately $1.0 billion, subject to adjustment and completion of due diligence and a definitive business combination agreement. A copy of the LOI is filed as Exhibit 10.1 to the 8-K.

Key Details

• Parties: Drugs Made In America Acquisition Corp. (the Company) and Power Analytics Global Corp. (the Target).
• Proposed valuation: approximately $1.0 billion, subject to adjustment based on due diligence, capital structure, net debt, working capital and market conditions.
• Status: Terms are preliminary; transaction remains subject to further negotiation and execution of a definitive business combination agreement.
• Filing: LOI attached as Exhibit 10.1 to the Form 8-K filed April 8, 2026 (Item 8.01 disclosure).

Why It Matters This LOI signals that the SPAC is pursuing a specific target and a potential business combination that could make Power Analytics a publicly traded company. For investors, the key facts are the preliminary $1.0 billion valuation estimate and that material terms remain subject to change pending due diligence and a definitive agreement. Because this is an LOI (not a definitive agreement), there is no guarantee the transaction will be completed; investors should watch for future filings with definitive terms, financial disclosures, and shareholder vote requirements.